Jamie P. Dwyer

Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease

Deepak L. Bhatt, Michael Szarek, Bertram Pitt et al. · New England Journal of Medicine · 2020 · 1.2K citations · Full text

Pharmacy, Nephrology, Pharmacotherapy +17

Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE–TIMI 58 randomised trial

Ofri Mosenzon, Stephen D. Wiviott, Avivit Cahn et al. · The Lancet Diabetes & Endocrinology · 2019 · 675 citations · Full text

Medicine, Nephrology, Pharmacology +14

Age-stratified and blood-pressure-stratified effects of blood-pressure-lowering pharmacotherapy for the prevention of cardiovascular disease and death: an individual participant-level data meta-analysis

Kazem Rahimi, Zeinab Bidel, Milad Nazarzadeh et al. · The Lancet · 2021 · 321 citations · Full text

Pharmacy, Geriatric Medicine, Pharmacology +17

Estimating Baseline Kidney Function in Hospitalized Patients with Impaired Kidney Function

Edward D. Siew, T. Alp İkizler, Michael E. Matheny et al. · Clinical Journal of the American Society of Nephrology · 2012 · 297 citations

Medicine, Nephrology, Norm-referenced Assessment +16

Rationale and protocol of the Dapagliflozin And Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial

Hiddo J.L. Heerspink, Bergur V. Stefánsson, Glenn M. Chertow et al. · Nephrology Dialysis Transplantation · 2019 · 216 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17